

Table SII. Clinical response rates at Week 52 for patients initially randomized to ixekizumab (IXE), including and excluding data from visits with IXE every 2 weeks dose escalation (modified nonresponder imputation)

	IXE <i>n</i> = 75 ^a <i>n</i> (%)	IXE, data from visits with IXE Q2W dosing during OLTP excluded <i>n</i> = 75 ^a <i>n</i> (%)
sPGA-G 0/1	59 (79.1)	61 (81.3)
sPGA-G 0	48 (63.5)	48 (63.5)
Overall sPGA 0/1	58 (77.1)	62 (82.6)
Overall sPGA 0	38 (50.3)	41 (54.4)

^aAnalysis population includes all patients initially randomized to IXE Q2W at Week 0. Q2W: every 2 weeks; OLTP: open-label treatment period; Q4W: every 4 weeks; sPGA: static Physician's Global Assessment; sPGA-G: sPGA of Genitalia.